Capital Advantage Exits Position in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Capital Advantage has sold out all of its stake in Abbott Laboratories during the most recent quarter, according to the disclosure filed by the company on Aug 10, 2016 with the SEC. The investment management company has sold out 5,071 shares of Abbott Laboratories which is valued at $228,398.

Other Hedge Funds, Including , Pictet Bank Trust Ltd reduced its stake in ABT by selling 56,906 shares or 37.53% in the most recent quarter. The Hedge Fund company now holds 94,720 shares of ABT which is valued at $4,266,189. Abbott Laboratories makes up approx 1.56% of Pictet Bank Trust Ltd’s portfolio.Vestor Capital boosted its stake in ABT in the latest quarter, The investment management firm added 2,869 additional shares and now holds a total of 234,926 shares of Abbott Laboratories which is valued at $10,576,369. Abbott Laboratories makes up approx 2.89% of Vestor Capital’s portfolio.Chicago Partners Investment Group boosted its stake in ABT in the latest quarter, The investment management firm added 1,300 additional shares and now holds a total of 3,900 shares of Abbott Laboratories which is valued at $175,695. Abbott Laboratories makes up approx 0.08% of Chicago Partners Investment Group’s portfolio.Buckingham Asset Management reduced its stake in ABT by selling 8,492 shares or 30.47% in the most recent quarter. The Hedge Fund company now holds 19,380 shares of ABT which is valued at $871,131. Abbott Laboratories makes up approx 0.29% of Buckingham Asset Management’s portfolio.Harvey Investment Co reduced its stake in ABT by selling 200 shares or 0.08% in the most recent quarter. The Hedge Fund company now holds 244,943 shares of ABT which is valued at $10,961,199. Abbott Laboratories makes up approx 2.31% of Harvey Investment Co’s portfolio.

Abbott Laboratories closed down -0.12 points or -0.27% at $44.24 with 94,39,877 shares getting traded on Friday. Post opening the session at $44.17, the shares hit an intraday low of $43.645 and an intraday high of $44.31 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.